佛跳官网永久免费加速

佛跳官网永久免费加速

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

佛跳官网永久免费加速

Learn More
Folded page of a newspaper

佛跳官网永久免费加速

佛跳官网永久免费加速

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

佛跳官网永久免费加速

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

佛跳官网永久免费加速

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

佛跳官网永久免费加速

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

佛跳官网永久免费加速

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

佛跳官网永久免费加速

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis

萝卜加速器  胡萝卜加速器app官方下载  韩国梯子加速器  洋葱tor加速器  老王加速2.2.25  老佛爷vp加速器2024